Science Pool

The Antimalarial MMV688533 provides Potential for Single-dose Cures with a High Barrier to Plasmodium Falciparum Parasite Resistance

The need for antimalarial drugs is urgent in the face of growing resistance to existing therapies. Murithi et al. characterized MMV688533, an acylguanidine identified from compounds inhibiting known human drug targets that were screened for activity against Plasmodium falciparum